GAITHERSBURG, Md., Jan. 3, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that it will participate in the 42th Annual J.P. Morgan Healthcare Conference.
Conference Details: | |||||
Presentation and Q&A | |||||
Date: | Monday, January 8, 2024 | ||||
Time: | 5:15 – 5:55 p.m. Pacific Standard Time (PST) | ||||
Location: | Westin St. Francis Hotel in San Francisco, California | ||||
Moderator: | Eric Joseph, Ph.D., Executive Director, Biotechnology Equity Research | ||||
Novavax participants: | John C. Jacobs, President and Chief Executive Officer | ||||
Conference | |||||
Event: | Investor Meetings | ||||
Date: | Monday, January 8, 2024 |
Recordings
A replay of the recorded presentation and Q&A will be available through the Events & presentations page of the Company's website at ir.novavax.com for 30 days from the date of the conference.
About Novavax
Novavax, Inc. (Nasdaq: NVAX) promotes improved health by discovering, developing and commercializing innovative vaccines to help protect against serious infectious diseases. Novavax, a global company based in Gaithersburg, Md., U.S., offers a differentiated vaccine platform that combines a recombinant protein approach, innovative nanoparticle technology and Novavax's patented Matrix-M adjuvant to enhance the immune response. Focused on the world's most urgent health challenges, Novavax is currently evaluating vaccines for COVID-19, influenza and COVID-19 and influenza combined. Please visit novavax.com and LinkedIn for more information.
Contacts:
Investors
Erika Schultz
240-268-2022
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media
Ali Chartan
240-720-7804
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$9.13 |
Daily Change: | -0.47 -4.90 |
Daily Volume: | 1,616,470 |
Market Cap: | US$1.460B |
December 13, 2024 December 10, 2024 November 11, 2024 October 16, 2024 |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREAstria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MOREEnd of content
No more pages to load